Methods of preparing papillomavirus nucleic acid transfer vectors, in-disassembled cluding by disassembly/reassembly of papillomavirus L1 and L2 virus-like particles, in a defined, cell-free high-efficiency production protocol. These methods may be used to efficiently encapsidate desired moieties, e.g., toxic or therapeutic nucleic acids such as DNA and RNA, and the resultant pseudovirus particles may be used as in vivo delivery vehicles.

Disclosed are a mutated HPV11 L1 protein (or a variant thereof), a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein (or a variant thereof) and the virus-like particle can induce the generation of neutralizing antibodies against at least two HPV types (e.g. HPV11 and HPV6), and therefore can be used to prevent infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum. Also disclosed is use of the protein and the virus-like particle in the manufacture of a pharmaceutical composition or a vaccine for preventing infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum.

The present invention relates to an encapsulin protein and a fusion protein comprising the same, and more specifically to a recombinant expression vector for vaccine production, and a preparation method therefor, the vector comprising polynucleotides that encode a target protein, an encapsulin protein and an RNA interacting domain (RID) protein, so as to improve the expression efficiency of the target protein, and thus enables a water-soluble vaccine to be produced in a highly efficient manner and a large target protein to be used.

The present invention relates to a human papillomavirus type 31 chimeric protein and a use thereof. Specifically, the present invention relates to a human papillomavirus chimeric protein, containing or being composed of an HPV31L1 protein or HPV31L1 protein mutant, and a polypeptide derived from an HPV73L2 protein and inserted into the HPV31L1 protein or HPV31L1 protein mutant, wherein the HPV31L1 protein is as shown in SEQ ID No. 1, and the HPV73L2 protein is as shown in SEQ ID No. 2.

This invention relates to chimeric virus-like particles (VLPs) assembled from a polypeptide comprising a papilloma virus (PV) L1 protein or L1/L2 protein and a target peptide comprising a CD8+ T cell epitope derived from a human pathogen. This invention also relates to methods using the chimeric VLPs as antigen-specific redirectors of immune responses.

A non-human papilloma pseudovirus or virus like particle has at least one papilloma capsid protein codon-optimized for expression in eukaryotic cells or cell lines. A pharmaceutical composition includes the non-human papilloma pseudovirus or virus like particle, and a diagnostic agent, an imaging agent, and a therapeutic agent. A non-human papilloma pseudovirus or virus like particle can be used as a medicament. A method for producing a non-human papilloma pseudovirus or virus like particle involves codon-optimizing of capsid proteins of non-human papillomaviruses for expression in eukaryotic cells, synthesizing of the sequences and cloning of the synthesized sequences into expression vectors, and producing non-human papilloma pseudovirus or virus like particles. .Math.-carrageenan can be used as transduction enhancer for non-human papilloma pseudovirus or virus like particles in vitro.

This invention is directed to immunogenic composition, conjugates, virus-lie particles (VLP) compositions, vaccines and methods directed to the treatment and/or prevent of infection by Human Papillomavirus.

The present invention relates to Coronavirus 2019-nCOV spike protein, polynucleotides encoding said spike protein, antibodies and vaccines for treatment or prevention of 2019-nCOV infection.

The disclosure relates to vaccination compositions, for example, against human papillomavirus, Zika virus, and flu virus. The disclosure also relates to vectors for producing the virus-like particles and immune complex platforms of the vaccination compositions.

A transdermal delivery system of microneedles containing a bioactive material, comprising at least one layer of a support material; at least one biodegradable needle associated with the support material, each needle comprising at least one biodegradable polymer and at least one sugar, wherein each biodegradable needle is hollow and is adapted to retain a bioactive material.